Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 0.49 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21609072 | 0.75 | KDR (0.50) | EPHX2KITKDRFLT3 | |
| SCHEMBL21660472 | 0.75 | KCNA5 (0.37) | EPHX2KCNA5KITKDRFLT3 | |
| SCHEMBL1782414 | 0.72 | KCNA5 (0.58) | KCNA5 | |
| SCHEMBL1784179 | 0.69 | SGMS2 (0.46) | KCNA5 | |
| SCHEMBL11450556 | 0.66 | EPHX2 (0.54) | EPHX2KCNA5 | |
| SCHEMBL30298447 | 0.66 | EPHX2 (0.54) | EPHX2KCNA5 | |
| SCHEMBL6990623 | 0.66 | FAAH (0.36) | EPHX2KCNA5KITKDRFLT3 | |
| SCHEMBL23064307 | 0.66 | EPHX2 (0.45) | EPHX2HSD17B10 | |
| SCHEMBL2305521 | 0.65 | CYP2C19 (0.49) | EPHX2CYP2D6CYP2C19ALDH1A1CYP3A4 | |
| SCHEMBL12426072 | 0.65 | SGMS2 (0.39) | EPHX2KCNA5KITKDRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200039945-A1 | Compounds | CTXT PTY LIMITED (AU) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039945-A1 | Compounds | SLC10A1, ABCB11, PCSK9 | EPHX2 2460/4885KCNA5 674/4885CYP2D6 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.